share_log

Will Caribou Biosciences (NASDAQ:CRBU) Spend Its Cash Wisely?

Will Caribou Biosciences (NASDAQ:CRBU) Spend Its Cash Wisely?

Caribou Biosciences (納斯達克股票代碼:CRBU)是否明智地利用了現金?
Simply Wall St ·  07/17 12:37

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

僅因業務未盈利並不意味着股價會下跌。例如,雖然軟件即服務業務Salesforce.com 多年來一直虧損,但與此同時,由於其不斷增長的經常性營業收入,自2005年以來持有該股,你的收益將十分可觀。儘管如此,忽視虧損公司過快消耗現金的風險的只有傻瓜。

So, the natural question for Caribou Biosciences (NASDAQ:CRBU) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

那麼,Caribou Biosciences(NASDAQ:CRBU)的股東們自然會問,它的現金燒燬率是否應該引起擔憂。在本篇報告中,我們將考慮該公司的年度負自由現金流,以後簡稱爲“現金燒燬”來與其現金儲備進行比較,以計算其現金儲備週期。

Does Caribou Biosciences Have A Long Cash Runway?

Caribou Biosciences有長期現金儲備週期嗎?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. As at March 2024, Caribou Biosciences had cash of US$294m and no debt. Importantly, its cash burn was US$115m over the trailing twelve months. Therefore, from March 2024 it had 2.6 years of cash runway. That's decent, giving the company a couple years to develop its business. You can see how its cash balance has changed over time in the image below.

現金儲備週期被定義爲公司保持其現金燒燬速度不變的情況下,耗盡其現金的時間長度。截至2024年3月,Caribou Biosciences有2.94億美元的現金儲備和無債務,其現金燒燬在過去的12個月中爲1.15億美元。因此,從2024年3月開始,它有2.6年的現金儲備週期。這相當不錯,給了該公司幾年時間來發展業務。您可以在下面的圖像中看到其現金餘額的變化情況。

big
NasdaqGS:CRBU Debt to Equity History July 17th 2024
納斯達克GS:CRBU的債務權益歷史記錄於2024年7月17日。

How Well Is Caribou Biosciences Growing?

Caribou Biosciences的增長情況如何?

At first glance it's a bit worrying to see that Caribou Biosciences actually boosted its cash burn by 9.0%, year on year. Given that its operating revenue increased 127% in that time, it seems the company has reason to think its expenditure is working well to drive growth. If revenue is maintained once spending on growth decreases, that could well pay off! It seems to be growing nicely. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

乍一看,讓人有些擔憂的是,Caribou Biosciences的現金燒燬率實際上同比增長了9.0%。考慮到其運營收入在此期間增長了127%,似乎該公司有理由認爲其支出推動了增長。如果收入在支出減少後能得到維持,那可能會產生好處!它似乎正在不斷增長。儘管過去總是值得研究的,但最重要的是未來。出於這個原因,看一下我們公司的分析師預測是很有意義的。

Can Caribou Biosciences Raise More Cash Easily?

Caribou Biosciences能輕鬆籌集更多資金嗎?雖然Caribou Biosciences似乎處於一個不錯的位置,但我們認爲它仍然值得考慮,如果需要的話,如何輕鬆籌集更多資金。公司可以通過債務或權益籌集資本。通過將公司的年度現金燒燬與其總市值進行比較,我們可以大致估算出它需要發行多少股才能維持公司運營,以便在未來一年內(以相同的燒燬速率)不用把公司運作所需的現金耗盡。

While Caribou Biosciences seems to be in a decent position, we reckon it is still worth thinking about how easily it could raise more cash, if that proved desirable. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Caribou Biosciences的市值爲1.92億美元,在去年耗盡了1.15億美元,這佔公司市值的60%。從這個角度來看,公司花費相對於市值而言是巨大的,我們非常擔心資本籌集會很痛苦。

Caribou Biosciences has a market capitalisation of US$192m and burnt through US$115m last year, which is 60% of the company's market value. From this perspective, it seems that the company spent a huge amount relative to its market value, and we'd be very wary of a painful capital raising.

Caribou Biosciences的現金燒燬情況有多危險?儘管相對於市值而言,其現金燒燬讓我們有些緊張,但我們不得不提到,我們認爲Caribou Biosciences的營收增長相對較爲可觀。儘管我們認爲它的現金燒燬沒有問題,但我們在本文中所做的分析仍然表明,股東們應該深思未來籌集更多資金的潛在成本。深入分析後,我們發現Caribou Biosciences有4個警告信號,您應該注意其中的1個,其中一個讓我們感到不安。

How Risky Is Caribou Biosciences' Cash Burn Situation?

Caribou Biosciences的現金燒燬情況有多危險?

Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Caribou Biosciences' revenue growth was relatively promising. Even though we don't think it has a problem with its cash burn, the analysis we've done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. Taking a deeper dive, we've spotted 4 warning signs for Caribou Biosciences you should be aware of, and 1 of them doesn't sit too well with us.

即使相對於市值而言,其現金燒燬狀況讓我們有些緊張,但我們不得不提到,我們認爲Caribou Biosciences的營收增長相對較爲有前途。儘管我們認爲它的現金燒燬沒有問題,但我們在本文中所做的分析仍然表明,股東們應該深思未來籌集更多資金的潛在成本。深入分析後,我們發現Caribou Biosciences有4個警告信號,您應該注意其中的1個,其中一個讓我們感到不安。

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

如果您希望查詢其他基本面更好的公司,則不要錯過具有高淨資產回報率和低債務的有趣公司免費列表,或者這個預計所有股票都會增長的股票列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論